Theravance Biopharma Inc. (NASDAQ:TBPH) shares traded up 3.4% during trading on Tuesday . The stock traded as high as $28.10 and last traded at $27.98, with a volume of 176,915 shares. The stock had previously closed at $27.05.

Several research analysts have commented on the stock. Leerink Swann reissued a “buy” rating on shares of Theravance Biopharma in a research note on Saturday, June 4th. Bank of America Corp. downgraded shares of Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research note on Wednesday, August 3rd. Guggenheim assumed coverage on shares of Theravance Biopharma in a research note on Monday, June 20th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, August 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $29.00.

The stock’s market cap is $1.34 billion. The stock has a 50-day moving average of $24.87 and a 200 day moving average of $21.19.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. On average, equities analysts forecast that Theravance Biopharma Inc. will post ($4.03) EPS for the current fiscal year.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 49,122 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $27.46, for a total value of $1,348,890.12. Following the completion of the transaction, the executive vice president now directly owns 241,686 shares in the company, valued at approximately $6,636,697.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brett K. Haumann sold 9,509 shares of the company’s stock in a transaction that occurred on Friday, August 19th. The stock was sold at an average price of $27.97, for a total value of $265,966.73. Following the completion of the transaction, the senior vice president now owns 197,391 shares of the company’s stock, valued at $5,521,026.27. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Theravance Biopharma stock. Schwab Charles Investment Management Inc. raised its stake in Theravance Biopharma Inc. (NASDAQ:TBPH) by 20.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 89,274 shares of the biopharmaceutical company’s stock after buying an additional 15,258 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.24% of Theravance Biopharma worth $1,464,000 at the end of the most recent quarter.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.